Mapi Pharma
  • About
        • Our Company
        • Our Strategy
        • R&D & Facilities
        • Team
  • Products
        • Lead Products
        • Glatiramer Acetate Depot
        • Complex API & Formulations
        • IP & New Chemical Entity
        • Marketed Products
  • News & Events
        • Press Releases
        • Events & Presentations
  • Contact
Select Page

Apremil 30 mg

For more information about this product please see:

Israel MOH-The Israeli Drug Registry-Apremil

To report side effects, please contact: [email protected]

To report a defect in the product, please contact: [email protected]

Mapi Pharam LTD Logo

Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting injections, complex active pharmaceutical ingredients (APIs) and formulations. The company’s lead product is Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly IM injection of 40mg GA for the treatment of multiple sclerosis (a $20 billion market). Mapi is engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia and other long acting Depot injectable treatments. Mapi Pharma Ltd. was founded in 2008 and is located in Ness Ziona, Israel and has GMP approved API and FDF facilities.

Contact

Address

Weizmann Science Park
16 Einstein St.
Ness Ziona, Israel 7403620

  • +972-73-7121213
  • +972-8-9100154
  • [email protected]

Sign Up to Receive Latest News

    Copyright © 2025 Mapi-Pharma Ltd. All rights reserved.
    Terms of Use
    Design by: Mentus